SCHEMBL2897225

SCHEMBL2897225

CC(C)c1ncc(C(=O)O)c(NCc2ccco2)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REN P00797 9/20 0.57
KDM4E B2RXH2 5/20 0.51
KDM6B O15054 1/20 0.51
KDM4A O75164 1/20 0.51
KDM5C P41229 1/20 0.51
KDM4D Q6B0I6 1/20 0.51
KDM4C Q9H3R0 1/20 0.51
CCNB2 O95067 1/20 0.44
CDK1 P06493 1/20 0.44
CCNB1 P14635 1/20 0.44
CCNB3 Q8WWL7 1/20 0.44
ALDH1A1 P00352 5/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
MAPT P10636 4/20 0.44
HSD17B10 Q99714 2/20 0.44
TSHR P16473 1/20 0.44
PKM P14618 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
LMNA P02545 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2902099 0.84 REN (0.55) RENKDM4EKDM6BKDM4AKDM5C
SCHEMBL2902514 0.82 KDM4E (0.52) RENKDM4EKDM6BKDM4AKDM5C
SCHEMBL2892637 0.81 REN (0.57) RENKDM4EKDM6BKDM4AKDM5C
SCHEMBL2900632 0.81 KDM4E (0.58) RENKDM4EKDM6BKDM4AKDM5C
SCHEMBL2902262 0.80 PDE5A (0.58) RENKDM4EKDM6BKDM4AKDM5C
SCHEMBL2900583 0.79 KDM4E (0.51) RENKDM4EKDM6BKDM4AKDM5C
SCHEMBL2903504 0.79 REN (0.53) RENALDH1A1SMN1; SMN2TDP1
SCHEMBL2894152 0.78 KDM4E (0.50) RENKDM4EKDM6BKDM4AKDM5C
SCHEMBL2900591 0.78 REN (0.53) RENALDH1A1SMN1; SMN2TDP1
SCHEMBL3016959 0.78 REN (0.53) RENKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2202228-B1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL (JP) 2014-12-10 EP disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
EP-2202228-A1 AMIDE COMPOUNDS AND USE OF THE SAME Takeda Pharmaceutical Company Limited (JP) 2010-06-30 EP disclosed
EP-2202228-A1 AMIDE COMPOUNDS AND USE OF THE SAME Takeda Pharmaceutical Company Limited (JP) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME REN, ACE, AGT REN 1/4885KDM4E 1257/4885KDM6B 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.